IBS is a common gastrointestinal disorder characterized by chronic abdominal pain and altered bowel habits.
Prevalence in the United States ranges from 7% to 16%, with higher occurrence in women and young individuals.
Annual direct costs associated with IBS exceed $1 billion in the United States.
Traditionally, IBS diagnosis relies on symptom identification related to various IBS subtypes (e.g., IBS with diarrhea, IBS with constipation, functional diarrhea, etc.).
Dysfunctions in gastrointestinal motor and sensory mechanisms contribute to IBS symptoms.
Alarm symptoms (e.g., unintentional weight loss, rectal bleeding) should be excluded during diagnosis1.
Symptom-based diagnosis involves assessing abdominal pain, bowel dysfunction, and bloating.
Additional history for somatoform and psychological disorders is valuable.
Physical examination (including digital rectal examination) and screening tests help exclude organic
Accumulating evidence suggests that HBOT may be effective for IBD. A systematic review analyzed 19 studies involving 809 patients. Here are the key findings:
Ulcerative Colitis: 87% clinical remission rate
Luminal Crohn’s Disease: 88% clinical remission rate
Perianal Crohn’s Disease: 60% clinical remission rate
Pouch Disorders: 31% clinical remission rate
Pyoderma Gangrenosum: 92% clinical remission rate
Perianal Sinus/Metastatic Crohn’s Disease: 65% clinical remission rate
15% of patients experienced minor adverse events.
These research articles underscores the benefits of hyperbaric oxygen therapy for individuals with Inflammatory Bowel Disease (IBD), including Crohn’s Disease and Ulcerative Colitis. .
If you have questions about a particular symptom or condition related to inflammatory bowel disease (IBD) , feel free to ask!
Learn about purchase and rental programs.
Newtowne 34″ Newtowne Hyperbaric Chamber
Copyright © 2024 Hyperbaric Hub LLC All Rights Reserved